Elesclomol induces copper‐dependent ferroptosis in colorectal cancer cells via degradation of ATP7A

Wei Gao,Zhao Huang,Jiufei Duan,Edouard C. Nice,Jie Lin,Canhua Huang

DOI: https://doi.org/10.1002/1878-0261.13079

2021-09-15

Molecular Oncology

Abstract:Cancer cells reprogram their copper metabolism to adapt to adverse microenvironments, such as oxidative stress. The copper chelator elesclomol has been reported to have considerable anticancer efficacy, but the underlying mechanisms remain largely unknown. In this study, we found that elesclomol-mediated copper overload inhibits colorectal cancer both in vitro and in vivo. Elesclomol alone promotes the degradation of the copper transporter ATP7A, which retards the proliferation of colorectal cancer cells. This property distinguishes it from several other copper chelators. Combinational treatment of elesclomol and copper leads to copper retention within mitochondria due to ATP7A loss, leading to ROS accumulation, which in turn promotes the degradation of SLC7A11, thus further enhancing oxidative stress and consequent ferroptosis in CRC cells. This effect accounts for the robust antitumor activity of elesclomol against colorectal cancer, which can be reversed by the administration of antioxidants and ferroptosis inhibitors, as well as the overexpression of ATP7A. In summary, our findings indicate that elesclomol-induced copper chelation inhibits colorectal cancer by targeting ATP7A and regulating ferroptosis.

oncology